Travere Therapeutics drug approved for rare kidney disease

SAN DIEGO — Travere Therapeutics, a biotech centered each on treating uncommon ailments and distancing itself from controversial founder Martin Shkreli, on Friday gained accelerated approval for a drug that treats IgA nephropathy, a uncommon and lethal autoimmune illness that assaults the kidneys and may result in organ failure.

The drug, which might be bought beneath the identify Filspari, is a once-a-day oral pill that is available in 200-milligram and 400-milligram doses. The Meals and Drug Administration granted accelerated approval after interim outcomes from an ongoing Section 3 scientific trial discovered that the remedy considerably diminished protein ranges within the urine of sufferers, an oblique marker of improved kidney operate.